DNDi Addresses 'Alarming Lack' Of R&D For Neglected Diseases

In a Center for Global Health R&D Policy Assessment blog post, the third part of the center’s Product Development Partnership (PDP) mini-series, “Bernard Pecoul from the Drugs for Neglected Diseases initiative (DNDi) discusses their experience with partnerships to develop treatments for neglected diseases.” Pecoul writes, “DNDi exists because of the alarming lack of R&D for the most neglected diseases in the world, which affect the poorest people but do not represent lucrative ‘market potential’ for the pharmaceutical industry. Our objective at DNDi is to address this terrible gap between neglected patient needs and R&D and to bridge the innovation-to-access divide” (8/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.